Gene-editing firms form patent alliance against Editas, Broad
By Max Stendahl,
Boston Business Journal
| 12. 16. 2016
Four biotechs involved in the burgeoning field of gene editing announced a formal patent alliance on Friday that puts them at odds with two Cambridge institutions doing the same, Editas Medicine and The Broad Institute.
The four companies — Berkeley, California-based Caribou Biosciences, ERS Genomics of Ireland, and Cambridge-based firms CRISPR Therapeutics (Nasdaq: CRSP) and Intellia Therapeutics (Nasdaq: NTLA) — all licensed or sublicensed intellectual property regarding CRISPR/Cas9 gene-editing from the same source: biologist Emmanuelle Charpentier, the Regents of the University of California and the University of Vienna.
On the other side of the dispute is Editas (Nasdaq: EDIT), which has been using CRISPR technology developed by Feng Zhang of the Broad Institute.
Charpentier and Zhang have each received patents for CRISPR/Cas9, a method of cutting out and replacing part of a gene that has the potential to revolutionize the treatment of serious genetic disorders. Their backers — UC Berkeley and the Broad, respectively — are currently duking it out in a court case in Virginia before the U.S. Patent and Trademark Office. A decision is expected in coming...
Related Articles
By Natalie Ram, Anya E. R. Prince, Jessica L. Roberts, Dov Fox, and Kayte Spector-Bagdady, Science | 09.11.2025
After declaring bankruptcy in March 2025, direct-to-consumer (DTC) genetic testing company 23andMe sold the data of more than 15 million people around the world to TTAM Research Institute, a nonprofit organization created by 23andMe’s founder and long-time CEO. 23andMe’s customers...
By Gina Kolata, The New York Times | 09.22.2025
On May 26, Tracy Atteberry checked in to the hospital at the National Institutes of Health in Bethesda, Md. The 57-year-old has an ultrarare inherited disease that hobbles his immune system so that the most innocuous of germs could kill...
By Dennis Sponer, BioSpace | 09.03.2025
Imagine telling a child with sickle cell disease that a cure exists—but it’s too expensive for their insurer to cover. That’s not a hypothetical. It’s the reality of gene therapy today: a revolutionary medical breakthrough caught in the bottleneck of...
By Ryan Cross, Endpoints News | 08.19.2025
Human eggs are incredibly rare cells. The ovary typically produces only 400 mature eggs across a woman’s life. But biologists in George Church’s lab at Harvard University — a group that’s never content with nature’s limits — just got a...